Trending NewsTrending NewsNYSE:NVO Novo Nordisk A/S (NVO) Stock Price, News & Analysis $38.81 +0.19 (+0.50%) Closing price 09/25/2026 03:59 PM EasternExtended Trading$38.80 -0.02 (-0.04%) As of 09/25/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Novo Nordisk A/S Stock (NYSE:NVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novo Nordisk A/S alerts:Sign Up Key Stats Today's Range$38.41▼$38.8350-Day Range$38.19▼$51.5652-Week Range$35.12▼$64.16Volume9.92 million shsAverage Volume12.68 million shsMarket Capitalization$173.30 billionP/E Ratio9.49Dividend Yield2.11%Price Target$64.94Consensus RatingHold Company Overview Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders. Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies. Novo Nordisk’s products are marketed in numerous countries worldwide and are supported by research, manufacturing and commercial operations across multiple regions. Novo Nordisk was formed through the 1989 merger of Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, two Danish companies that had developed insulin treatments in the early twentieth century. Maziar Mike Doustdar serves as president and chief executive officer, while Helge Lund serves as chair of the board of directors.AI Generated. May Contain Errors. Read More Novo Nordisk A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreNVO MarketRank™: Novo Nordisk A/S scored higher than 89% of companies evaluated by MarketBeat, and ranked 43rd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingNovo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on no strong buy ratings, 3 buy ratings, 14 hold ratings, and 1 sell rating.Upside PotentialNovo Nordisk A/S has a consensus price target of $64.94, representing about 67.3% upside from its current price of $38.81.Amount of Analyst CoverageNovo Nordisk A/S has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Novo Nordisk A/S's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-3.66% Earnings GrowthEarnings for Novo Nordisk A/S are expected to decrease by -3.66% in the coming year, from $3.55 to $3.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novo Nordisk A/S is 9.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Novo Nordisk A/S is 9.49, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.42.Price to Earnings Growth RatioNovo Nordisk A/S has a PEG Ratio of 1.26. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovo Nordisk A/S has a P/B Ratio of 5.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novo Nordisk A/S's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.59% of the float of Novo Nordisk A/S has been sold short.Short Interest Ratio / Days to CoverNovo Nordisk A/S has a short interest ratio ("days to cover") of 2.92, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novo Nordisk A/S has recently decreased by 16.78%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovo Nordisk A/S pays a meaningful dividend of 2.11%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovo Nordisk A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novo Nordisk A/S is 20.05%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 23.98% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.Read more about Novo Nordisk A/S's dividend. News and Social Media2.8 / 5News Sentiment0.44 News SentimentNovo Nordisk A/S has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 77 news articles for Novo Nordisk A/S this week, compared to 8 articles on an average week.Search InterestOnly 67 people have searched for NVO on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows29 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 32% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.Percentage Held by Insiders0.07% of the stock of Novo Nordisk A/S is held by insiders.Percentage Held by Institutions11.54% of the stock of Novo Nordisk A/S is held by institutions.Read more about Novo Nordisk A/S's insider trading history. Receive NVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVO Stock News HeadlinesEli Lilly (LLY) vs. Novo Nordisk (NVO): Has the GLP-1 Race Changed the Moat?59 minutes ago | finance.yahoo.comNovo Nordisk Changed the World With Its GLP-1 Weight-Loss Drugs. Now It Wants to Help Cure Baldness.September 25 at 11:55 PM | finance.yahoo.comOctober 7th dollar deadlineFormer hedge fund manager Larry Benedict called the 2020 market drop and the 2022 downturn before they happened. Now he's pointing to October 7 as a critical date for the US dollar. He says a federal deadline on that day could hit some of the biggest AI stock winners, with gains potentially cut by as much as 40 percent. Benedict is hosting a free briefing to walk through a three-step approach he believes could help investors prepare.September 26 at 1:00 AM | Brownstone Research (Ad)Could This Be Novo Nordisk's Next Billion-Dollar Weight-Loss Product?September 25 at 6:00 PM | fool.comNovo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should KnowSeptember 25 at 1:54 PM | finance.yahoo.comNovo Pays Up to $1.3 Billion for Nanexa's Drug Delivery TechSeptember 25 at 1:54 PM | finance.yahoo.comViking's Obesity Edge May Be Staying Power, Not Weight Loss (NVO)Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.September 23 at 1:20 PM | marketbeat.comEli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.September 23 at 9:15 AM | marketbeat.comSee More Headlines NVO Stock Analysis - Frequently Asked Questions How have NVO shares performed this year? Novo Nordisk A/S's stock was trading at $50.88 at the beginning of the year. Since then, NVO stock has decreased by 23.7% and is now trading at $38.8130. How were Novo Nordisk A/S's earnings last quarter? Novo Nordisk A/S (NYSE:NVO) announced its earnings results on Tuesday, June, 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The company earned $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a trailing twelve-month return on equity of 58.61%. When did Novo Nordisk A/S's stock split? Novo Nordisk A/S shares split on Wednesday, September 20th 2023.The 2-1 split was announced on Wednesday, September 20th 2023. The newly created shares were issued to shareholders after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Novo Nordisk A/S have any subsidiaries? Novo Nordisk A/S subsidiaries include Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and others. Who are Novo Nordisk A/S's major shareholders? Novo Nordisk A/S's top institutional shareholders include State Street Corp (0.13%), Envestnet Asset Management Inc. (0.09%), Saratoga Research & Investment Management (0.07%) and Van ECK Associates Corp (0.02%). View institutional ownership trends. How do I buy shares of Novo Nordisk A/S? Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novo Nordisk A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), ServiceNow (NOW), Advanced Micro Devices (AMD), Salesforce (CRM) and Eli Lilly and Company (LLY). Company Calendar Last Earnings6/30/2026Record date for 8/25 Dividend8/17/2026Ex-Dividend for 8/25 Dividend8/17/2026Dividend Payable8/25/2026Today9/26/2026EASD 20269/30/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 5 days ago, NVO's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:NVO CIK353278 Webwww.novonordisk.com Phone(454) 444-8888Fax45-4449-0555Employees69,505Year Founded1923Price Target and Rating Average Price Target for Novo Nordisk A/S$64.94 High Price Target$175.00 Low Price Target$40.00 Potential Upside/Downside+67.3%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)$4.09 Trailing P/E Ratio9.49 Forward P/E Ratio10.93 P/E Growth1.26Net Income$15.51 billion Net Margins35.36% Pretax Margin45.31% Return on Equity58.61% Return on Assets20.91% Debt Debt-to-Equity Ratio0.55 Current Ratio0.87 Quick Ratio0.66 Sales & Book Value Annual Sales$46.80 billion Price / Sales3.70 Cash Flow$4.71 per share Price / Cash Flow8.24 Book Value$6.58 per share Price / Book5.90Miscellaneous Outstanding Shares4,465,000,000Free Float4,461,875,000Market Cap$173.30 billion OptionableOptionable Beta0.74 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NYSE:NVO) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredMake this "Money Move" Before Midterms November 3rdAddison Wiggin has interviewed Warren Buffett, questioned two former Treasury Secretaries, and warned of the 2...Banyan Hill Publishing | SponsoredAmerica Can’t Afford to Lose This Race. But at What Cost?AI spending on data centers, chips and power infrastructure is exploding, and much of it is financed with heav...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novo Nordisk A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novo Nordisk A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
